Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma

Science Translational Medicine

Volumn 4, Issue 115, 2012, Pages

  Chanthery, Yvan H ^a,b   Gustafson, W Clay ^b,c   Itsara, Melissa ^b,c   Persson, Anders ^b,c   Hackett, Christopher S ^a,b   Grimmer, Matt ^b,c   Charron, Elise ^b,c   Yakovenko, Slava ^b,c   Kim, Grace ^b   Matthay, Katherine K ^b,c   Weiss, William A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; DOXYCYCLINE; GLYCOGEN SYNTHASE KINASE 3BETA; MACROGOL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; RECOMBINANT HUMAN INSULIN; ANGIOGENESIS INHIBITOR; IMIDAZOLE DERIVATIVE; MYCN PROTEIN, HUMAN; MYCN PROTEIN, MOUSE; NUCLEAR PROTEIN; ONCOPROTEIN; QUINOLINE DERIVATIVE;

ANGIOGENESIS; ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTO ONCOGENE; PROTO ONCOGENE MYCN; REAL TIME POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; BIOSYNTHESIS; BRAIN TUMOR; CANCER TRANSPLANTATION; GENE EXPRESSION REGULATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PARACRINE COMMUNICATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS; QUINOLINES; SIGNAL TRANSDUCTION;

EID: 84855374142     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3002977     Document Type: Article

References (36)

1. J. M. Maris, Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202-2211 (2010).
2. W. A. Weiss, K. Aldape, G. Mohapatra, B. G. Feuerstein, J. M. Bishop, Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J. 16, 2985-2995 (1997).
3. C. S. Hackett, J. G. Hodgson, M. E. Law, J. Fridlyand, K. Osoegawa, P. J. de Jong, N. J. Nowak, D. Pinkel, D. G. Albertson, A. Jain, R. Jenkins, J. W. Gray, W. A. Weiss, Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res. 63, 5266-5273 (2003).
4. D. Meitar, S. E. Crawford, A. W. Rademaker, S. L. Cohn, Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J. Clin. Oncol. 14, 405-414 (1996).
5. T. A. Baudino, C. McKay, H. Pendeville-Samain, J. A. Nilsson, K. H. Maclean, E. L. White, A. C. Davis, J. N. Ihle, J. L. Cleveland, c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16, 2530-2543 (2002).
6. I. Langer, P. Vertongen, J. Perret, J. Fontaine, G. Atassi, P. Robberecht, Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in human neuroblastomas. Med. Pediatr. Oncol. 34, 386-393 (2000).
7. A. S. Chung, J. Lee, N. Ferrara, Targeting the tumour vasculature: Insights from physiological angiogenesis. Nat. Rev. Cancer 10, 505-514 (2010).
8. U. E. Knies-Bamforth, S. B. Fox, R. Poulsom, G. I. Evan, A. L. Harris, c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res. 64, 6563-6570 (2004).
9. J. Kang, P. G. Rychahou, T. A. Ishola, J. M. Mourot, B. M. Evers, D. H. Chung, N-myc is a novel regulator of PI3K-mediated VEGF expression in neuroblastoma. Oncogene 27, 3999-4007 (2008).
10. A. Lasorella, G. Rothschild, Y. Yokota, R. G. Russell, A. Iavarone, Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. Mol. Cell. Biol. 25, 3563-3574 (2005).
11. A. M. Kenney, H. R. Widlund, D. H. Rowitch, Hedgehog and PI-3 kinase signaling converge on Nmyc1 to promote cell cycle progression in cerebellar neuronal precursors. Development 131, 217-228 (2004).
12. L. Chesler, C. Schlieve, D. D. Goldenberg, A. Kenney, G. Kim, A. McMillan, K. K. Matthay, D. Rowitch, W. A. Weiss, Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res. 66, 8139-8146 (2006).
13. J. I. Johnsen, L. Segerström, A. Orrego, L. Elfman, M. Henriksson, B. Kågedal, S. Eksborg, B. Sveinbjörnsson, P. Kogner, Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27, 2910-2922 (2008).
14. H. P. Gerber, A. McMurtrey, J. Kowalski, M. Yan, B. A. Keyt, V. Dixit, N. Ferrara, Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 273, 30336-30343 (1998).
15. C. R. Schnell, F. Stauffer, P. R. Allegrini, T. O'Reilly, P. M. McSheehy, C. Dartois, M. Stumm, R. Cozens, A. Littlewood-Evans, C. García- Echeverría, S. M. Maira, Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: Implications for clinical imaging. Cancer Res. 68, 6598-6607 (2008).
16. R. Sears, F. Nuckolls, E. Haura, Y. Taya, K. Tamai, J. R. Nevins, Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 14, 2501-2514 (2000).
17. L. C. Cantley, The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002).
18. D. C. Cho, M. B. Cohen, D. J. Panka, M. Collins, M. Ghebremichael, M. B. Atkins, S. Signoretti, J. W. Mier, The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 16, 3628-3638 (2010).
19. S. M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chène, A. De Pover, K. Schoemaker, D. Fabbro, D. Gabriel, M. Simonen, L. Murphy, P. Finan, W. Sellers, C. García- Echeverría, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).
20. W. Lutz, M. Stöhr, J. Schürmann, A. Wenzel, A. Löhr, M. Schwab, Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells. Oncogene 13, 803-812 (1996).
21. X. Zhao, D. D'Arca, W. K. Lim, M. Brahmachary, M. S. Carro, T. Ludwig, C. C. Cardo, F. Guillemot, K. Aldape, A. Califano, A. Iavarone, A. Lasorella, The N-Myc-DLL3 cascade is suppressed by the ubiquitin ligase Huwe1 to inhibit proliferation and promote neurogenesis in the developing brain. Dev. Cell 17, 210-221 (2009).
22. X. Zhao, J. I. Heng, D. Guardavaccaro, R. Jiang, M. Pagano, F. Guillemot, A. Iavarone, A. Lasorella, The HECT-domain ubiquitin ligase Huwe1 controls neural differentiation and proliferation by destabilizing the N-Myc oncoprotein. Nat. Cell Biol. 10, 643-653 (2008).
23. T. Teitz, J. J. Stanke, S. Federico, C. L. Bradley, R. Brennan, J. Zhang, M. D. Johnson, J. Sedlacik, M. Inoue, Z. M. Zhang, S. Frase, J. E. Rehg, C. M. Hillenbrand, D. Finkelstein, C. Calabrese, M. A. Dyer, J. M. Lahti, Preclinical models for neuroblastoma: Establishing a baseline for treatment. PLoS One 6, e19133 (2011).
24. A. G. Bader, S. Kang, L. Zhao, P. K. Vogt, Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5, 921-929 (2005).
25. H. Cui, T. Li, H. F. Ding, Linking of N-Myc to death receptor machinery in neuroblastoma cells. J. Biol. Chem. 280, 9474-9481 (2005).
26. S. Fulda, W. Lutz, M. Schwab, K. M. Debatin, MycN sensitizes neuroblastoma cells for drug-induced apoptosis. Oncogene 18, 1479-1486 (1999).
27. A. Bender, D. Opel, I. Naumann, R. Kappler, L. Friedman, D. von Schweinitz, K. M. Debatin, S. Fulda, PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis. Oncogene 30, 494-503 (2011).
28. M. Yada, S. Hatakeyama, T. Kamura, M. Nishiyama, R. Tsunematsu, H. Imaki, N. Ishida, F. Okumura, K. Nakayama, K. I. Nakayama, Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 23, 2116-2125 (2004).
29. T. Otto, S. Horn, M. Brockmann, U. Eilers, L. Schüttrumpf, N. Popov, A. M. Kenney, J. H. Schulte, R. Beijersbergen, H. Christiansen, B. Berwanger, M. Eilers, Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15, 67-78 (2009).
30. J. H. Mao, I. J. Kim, D. Wu, J. Climent, H. C. Kang, R. DelRosario, A. Balmain, FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 321, 1499-1502 (2008).
31. C. Schülein, M. Eilers, N. Popov, PI3K-dependent phosphorylation of Fbw7 modulates substrate degradation and activity. FEBS Lett. 585, 2151-2157 (2011).
32. J. R. Hall, E. Kow, K. R. Nevis, C. K. Lu, K. S. Luce, Q. Zhong, J. G. Cook, Cdc6 stability is regulated by the Huwe1 ubiquitin ligase after DNA damage. Mol. Biol. Cell 18, 3340-3350 (2007).
33. M. D. Hogarty, Mcl1 becomes ubiquitin-ous: New opportunities to antagonize a pro-survival protein. Cell Res. 20, 391-393 (2010).
34. H. Komuro, S. Kaneko, M. Kaneko, Y. Nakanishi, Expression of angiogenic factors and tumor progression in human neuroblastoma. J. Cancer Res. Clin. Oncol. 127, 739-743 (2001).
35. G. Qing, N. Skuli, P. A. Mayes, B. Pawel, D. Martinez, J. M. Maris, M. C. Simon, Combinatorial regulation of neuroblastoma tumor progression by N-Myc and hypoxia inducible factor HIF-1α. Cancer Res. 70, 10351-10361 (2010).
36. S. M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chène, A. De Pover, K. Schoemaker, D. Fabbro, D. Gabriel, M. Simonen, L. Murphy, P. Finan, W. Sellers, C. García- Echeverría, Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 7, 1851-1863 (2008).